Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings AstraZeneca PLC: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: AstraZeneca PLC
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses: AstraZeneca PLC
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

AstraZeneca PLC SectorGermany

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

AstraZeneca PLC SectorGermany

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

AstraZeneca PLC SectorGermany

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

AstraZeneca PLC SectorGermany

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

AstraZeneca PLC SectorGermany

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
299B
A
1,082B
A
633B
BBB
461B
AA
-
338B
AA
291B
AAA
222B
A
202B
A
163B
AA
139B
A
Average 383.1B
AA
Weighted average by Cap.
AA